Symbols / GLTO $28.69 -0.76% Galecto Inc

Healthcare • Biotechnology • Denmark • NCM
GLTO Chart
About

Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases. It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications. The company was founded in 2011 and is headquartered in Copenhagen, Denmark.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 1.73B
Enterprise Value 27.66M Income -15.84M Sales —
Book/sh 5.02 Cash/sh 5.73 Dividend Yield —
Payout 0.00% Employees 5 IPO Oct 29, 2020
P/E — Forward P/E -30.20 PEG —
P/S — P/B 5.71 P/C —
EV/EBITDA -2.33 EV/Sales — Quick Ratio 3.28
Current Ratio 3.73 Debt/Eq 0.90 LT Debt/Eq —
EPS (ttm) -12.11 EPS next Y -0.95 EPS Growth —
Revenue Growth — Earnings 2025-03-19 16:00 ROA -43.54%
ROE -109.49% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 60.24M
Shs Float 1.05M Short Float 0.46% Short Ratio 1.26
Short Interest — 52W High 38.33 52W Low 2.01
Beta 1.57 Avg Volume 161.02K Volume 231.44K
Target Price $46.75 Recom Strong_buy Prev Close $28.91
Price $28.69 Change -0.76%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$46.75
Mean price target
2. Current target
$28.69
Latest analyst target
3. DCF / Fair value
$-2.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.69
Low
$40.00
High
$57.00
Mean
$46.75

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-17 init UBS — → Buy $45
2026-02-17 main Guggenheim Buy → Buy $40
2026-01-07 init Leerink Partners — → Outperform $46
2025-12-08 main Guggenheim Buy → Buy $36
2025-12-01 init Guggenheim — → Buy $32
2024-10-17 main Oppenheimer Outperform → Outperform $10
2024-06-10 main Oppenheimer Outperform → Outperform $9
2023-09-28 down HC Wainwright & Co. Buy → Neutral —
2023-08-21 main HC Wainwright & Co. Buy → Buy $2
2023-08-15 down SVB Leerink Outperform → Market Perform $2
2023-08-01 reit Oppenheimer Outperform → Outperform $12
2023-08-01 reit HC Wainwright & Co. Buy → Buy $12
2023-06-20 init Oppenheimer — → Outperform $12
2023-05-24 reit HC Wainwright & Co. Buy → Buy $12
2023-05-15 init HC Wainwright & Co. — → Buy $12
2023-03-17 init Cantor Fitzgerald — → Overweight $16
2023-03-10 reit Credit Suisse — → Outperform $6
2022-08-03 main SVB Leerink — → Outperform $13
2021-08-06 main Credit Suisse — → Outperform $7
2021-03-16 main Credit Suisse — → Outperform $12
News
RSS: Latest GLTO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-09 FAIRMOUNT FUNDS MANAGEMENT LLC Director and Beneficial Owner of more than 10% of a Class of Security — 8,713,000 — —
2026-02-09 BRUNO JULIANNE Director — 129,000 — —
2026-01-05 HEWES LEMUEL BECKER Officer — 264,629 $0.00 $0
2026-01-05 SATTARZADEH SHERWIN Chief Operating Officer — 190,376 $0.00 $0
2026-01-02 SCHAMBYE HANS T. Chief Executive Officer — 1,360 — —
2026-01-02 WINSLOW GARRETT General Counsel — 680 — —
2026-01-02 FIRMANI LORI Chief Financial Officer — 374 — —
2026-01-02 SCHAMBYE HANS T. Chief Executive Officer — 700 $21.38 $14,966
2026-01-02 WINSLOW GARRETT General Counsel — 255 $21.38 $5,452
2026-01-02 FIRMANI LORI Chief Financial Officer — 135 $21.41 $2,890
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
210.87
+890.38%
21.29
-41.60%
36.46
-40.44%
61.21
Research And Development
201.19
+1764.05%
10.79
-54.59%
23.77
-50.69%
48.21
Selling General And Administration
9.69
-7.75%
10.50
-17.25%
12.69
-2.42%
13.00
General And Administrative Expense
9.69
-7.75%
10.50
-17.25%
12.69
-2.42%
13.00
Other Gand A
9.69
-7.75%
10.50
-17.25%
12.69
-2.42%
13.00
Total Expenses
210.87
+890.38%
21.29
-41.60%
36.46
-40.44%
61.21
Operating Income
-210.87
-890.38%
-21.29
+41.60%
-36.46
+40.44%
-61.21
Total Operating Income As Reported
-210.87
-847.31%
-22.26
+44.22%
-39.91
+34.80%
-61.21
EBITDA
-210.84
-898.71%
-21.11
+40.74%
-35.63
+41.32%
-60.72
Normalized EBITDA
-210.75
-945.35%
-20.16
+37.09%
-32.05
+46.21%
-59.58
Reconciled Depreciation
0.03
-81.22%
0.18
-78.19%
0.83
+69.39%
0.49
EBIT
-210.87
-890.38%
-21.29
+41.60%
-36.46
+40.44%
-61.21
Total Unusual Items
-0.08
+91.16%
-0.95
+73.47%
-3.58
-214.40%
-1.14
Total Unusual Items Excluding Goodwill
-0.08
+91.16%
-0.95
+73.47%
-3.58
-214.40%
-1.14
Special Income Charges
0.00
+100.00%
-0.97
+71.39%
-3.38
0.00
Restructuring And Mergern Acquisition
0.00
-100.00%
0.97
-71.93%
3.45
0.00
Net Income
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Pretax Income
-209.79
-880.41%
-21.40
+44.20%
-38.35
+37.77%
-61.62
Net Non Operating Interest Income Expense
1.17
+38.27%
0.84
-50.03%
1.69
+133.93%
0.72
Net Interest Income
1.17
+38.27%
0.84
-50.03%
1.69
+133.93%
0.72
Interest Income Non Operating
1.17
+38.27%
0.84
-50.03%
1.69
+133.93%
0.72
Interest Income
1.17
+38.27%
0.84
-50.03%
1.69
+133.93%
0.72
Other Income Expense
-0.08
+91.16%
-0.95
+73.47%
-3.58
-214.40%
-1.14
Gain On Sale Of Security
-0.08
-566.67%
0.02
+109.14%
-0.20
+82.70%
-1.14
Tax Provision
0.05
+21.95%
0.04
0.00
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Net Income From Continuing Operation Net Minority Interest
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Net Income From Continuing And Discontinued Operation
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Net Income Continuous Operations
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Normalized Income
-209.75
-923.74%
-20.49
+41.07%
-34.77
+42.52%
-60.48
Net Income Common Stockholders
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Diluted EPS
—
-18.53
+48.64%
-36.08
+40.61%
-60.75
Basic EPS
—
-18.53
+48.64%
-36.08
+40.61%
-60.75
Basic Average Shares
—
1.16
+8.87%
1.06
+4.58%
1.02
Diluted Average Shares
—
1.16
+8.87%
1.06
+4.58%
1.02
Diluted NI Availto Com Stockholders
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Gain On Sale Of PPE
—
0.00
-100.00%
0.06
0.00
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
260.53
+1420.70%
17.13
-55.18%
38.23
-47.77%
73.19
Current Assets
260.42
+1446.55%
16.84
-54.21%
36.77
-42.46%
63.91
Cash Cash Equivalents And Short Term Investments
257.62
+1717.45%
14.18
-57.24%
33.15
-44.95%
60.22
Cash And Cash Equivalents
257.62
+1717.45%
14.18
-33.96%
21.46
-34.53%
32.79
Other Short Term Investments
—
0.00
-100.00%
11.69
-57.41%
27.44
Receivables
0.90
+2.04%
0.88
-48.72%
1.72
+24.58%
1.38
Taxes Receivable
0.90
+2.04%
0.88
-48.72%
1.72
+24.58%
1.38
Prepaid Assets
0.58
-2.20%
0.59
-23.77%
0.77
-3.85%
0.81
Current Deferred Assets
1.20
+8.61%
1.10
+5.45%
1.05
-27.86%
1.45
Other Current Assets
0.12
+38.89%
0.09
+5.88%
0.09
+63.46%
0.05
Total Non Current Assets
0.10
-64.51%
0.29
-79.83%
1.45
-84.34%
9.28
Net PPE
0.10
-20.00%
0.13
-60.00%
0.33
-72.15%
1.17
Gross PPE
0.18
-2.22%
0.18
-49.15%
0.35
-71.20%
1.23
Accumulated Depreciation
-0.07
-44.00%
-0.05
-72.41%
-0.03
+53.23%
-0.06
Machinery Furniture Equipment
—
—
—
—
Other Properties
0.18
-2.22%
0.18
-49.15%
0.35
-71.20%
1.23
Investments And Advances
—
—
0.00
-100.00%
5.83
Other Investments
—
—
—
5.83
Other Non Current Assets
—
0.16
-85.55%
1.13
-50.50%
2.28
Total Liabilities Net Minority Interest
20.15
+1448.58%
1.30
-77.93%
5.90
-48.44%
11.44
Current Liabilities
20.07
+1576.36%
1.20
-79.47%
5.83
-47.51%
11.11
Payables And Accrued Expenses
18.53
+3569.11%
0.51
-87.75%
4.12
-56.60%
9.49
Payables
17.66
+4585.68%
0.38
-77.85%
1.70
-49.19%
3.35
Accounts Payable
0.44
+17.77%
0.38
-77.85%
1.70
-49.19%
3.35
Other Payable
17.22
—
—
—
Current Accrued Expenses
0.86
+575.00%
0.13
-94.71%
2.42
-60.63%
6.14
Pensionand Other Post Retirement Benefit Plans Current
0.44
+116.67%
0.20
-79.33%
0.99
+65.33%
0.60
Current Debt And Capital Lease Obligation
0.01
+25.00%
0.01
-93.44%
0.18
-61.55%
0.48
Current Capital Lease Obligation
0.01
+25.00%
0.01
-93.44%
0.18
-61.55%
0.48
Other Current Liabilities
1.08
+126.89%
0.48
-11.69%
0.54
+0.00%
0.54
Total Non Current Liabilities Net Minority Interest
0.08
-22.12%
0.10
+57.58%
0.07
-79.88%
0.33
Long Term Debt And Capital Lease Obligation
0.05
-13.11%
0.06
-7.58%
0.07
-79.88%
0.33
Long Term Capital Lease Obligation
0.05
-13.11%
0.06
-7.58%
0.07
-79.88%
0.33
Other Non Current Liabilities
0.03
-34.88%
0.04
—
—
Stockholders Equity
240.38
+1418.41%
15.83
-51.03%
32.33
-47.64%
61.75
Common Stock Equity
-175.87
-1315.35%
14.47
-55.24%
32.33
-47.64%
61.75
Capital Stock
416.25
+30506.84%
1.36
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Preferred Stock
416.25
+30506.84%
1.36
0.00
0.00
Share Issued
1.60
+21.29%
1.32
+21.44%
1.08
+5.69%
1.03
Ordinary Shares Number
1.60
+21.29%
1.32
+21.44%
1.08
+5.69%
1.03
Additional Paid In Capital
310.69
+6.44%
291.90
+1.34%
288.04
+2.97%
279.73
Retained Earnings
-487.36
-75.61%
-277.52
-8.37%
-256.08
-17.61%
-217.74
Gains Losses Not Affecting Retained Earnings
0.80
+726.80%
0.10
-74.47%
0.38
+255.74%
-0.24
Other Equity Adjustments
0.80
+726.80%
0.10
-74.47%
0.38
+255.74%
-0.24
Total Equity Gross Minority Interest
240.38
+1418.41%
15.83
-51.03%
32.33
-47.64%
61.75
Total Capitalization
240.38
+1418.41%
15.83
-51.03%
32.33
-47.64%
61.75
Working Capital
240.36
+1436.61%
15.64
-49.45%
30.94
-41.40%
52.80
Invested Capital
-175.87
-1315.35%
14.47
-55.24%
32.33
-47.64%
61.75
Total Debt
0.07
-6.85%
0.07
-70.68%
0.25
-69.03%
0.80
Capital Lease Obligations
0.07
-6.85%
0.07
-70.68%
0.25
-69.03%
0.80
Net Tangible Assets
240.38
+1418.41%
15.83
-51.03%
32.33
-47.64%
61.75
Tangible Book Value
-175.87
-1315.35%
14.47
-55.24%
32.33
-47.64%
61.75
Available For Sale Securities
—
—
—
5.83
Investmentin Financial Assets
—
—
0.00
-100.00%
5.83
Preferred Stock Equity
416.25
+30506.84%
1.36
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-6.73
+63.88%
-18.62
+49.55%
-36.91
+14.02%
-42.93
Cash Flow From Continuing Operating Activities
-6.73
+63.88%
-18.62
+49.55%
-36.91
+14.02%
-42.93
Net Income From Continuing Operations
-209.84
-878.77%
-21.44
+44.10%
-38.35
+37.77%
-61.62
Depreciation Amortization Depletion
0.03
-81.22%
0.18
-78.19%
0.83
+69.39%
0.49
Depreciation
0.03
-81.22%
0.18
-78.19%
0.83
+69.39%
0.49
Depreciation And Amortization
0.03
-81.22%
0.18
-78.19%
0.83
+69.39%
0.49
Other Non Cash Items
174.35
+8648.37%
1.99
+4232.61%
0.05
-20.69%
0.06
Stock Based Compensation
1.00
-69.19%
3.24
-40.32%
5.43
-2.58%
5.57
Operating Gains Losses
9.36
—
-0.06
-191.43%
0.07
Gain Loss On Investment Securities
9.36
—
—
0.07
Gain Loss On Sale Of PPE
—
0.00
+100.00%
-0.06
0.00
Change In Working Capital
18.36
+788.56%
-2.67
+38.97%
-4.37
-136.61%
11.94
Change In Prepaid Assets
-0.14
-114.47%
0.95
+1367.69%
0.07
-98.96%
6.23
Change In Payables And Accrued Expense
18.37
+511.54%
-4.46
+10.42%
-4.98
-176.84%
6.49
Change In Accrued Expense
1.10
+135.01%
-3.14
+5.88%
-3.33
-171.47%
4.67
Change In Payable
17.27
+1403.55%
-1.32
+19.60%
-1.65
-190.60%
1.82
Change In Account Payable
17.27
+1403.55%
-1.32
+19.60%
-1.65
-190.60%
1.82
Change In Other Current Assets
0.17
-82.89%
0.97
-15.51%
1.15
+546.69%
-0.26
Change In Other Current Liabilities
-0.04
+72.44%
-0.13
+78.83%
-0.60
-14.72%
-0.52
Investing Cash Flow
-17.37
-249.13%
11.65
-47.83%
22.33
+80.31%
12.38
Cash Flow From Continuing Investing Activities
-17.37
-249.13%
11.65
-47.83%
22.33
+80.31%
12.38
Net PPE Purchase And Sale
—
0.00
-100.00%
0.08
+142.35%
-0.20
Purchase Of PPE
—
—
0.00
+100.00%
-0.20
Sale Of PPE
—
0.00
-100.00%
0.08
0.00
Capital Expenditure
—
—
—
-0.20
Net Investment Purchase And Sale
0.00
-100.00%
11.65
-47.63%
22.25
+76.84%
12.58
Purchase Of Investment
—
0.00
+100.00%
-25.94
+42.19%
-44.87
Sale Of Investment
0.00
-100.00%
11.65
-75.82%
48.18
-16.12%
57.45
Net Business Purchase And Sale
-17.37
0.00
—
—
Purchase Of Business
-17.37
0.00
—
—
Financing Cash Flow
266.84
0.00
-100.00%
2.88
+467.26%
0.51
Cash Flow From Continuing Financing Activities
266.84
0.00
-100.00%
2.88
+467.26%
0.51
Net Common Stock Issuance
—
0.00
-100.00%
2.88
+467.26%
0.51
Proceeds From Stock Option Exercised
0.03
0.00
—
—
Changes In Cash
242.74
+3581.20%
-6.97
+40.43%
-11.71
+61.04%
-30.04
Effect Of Exchange Rate Changes
0.70
+322.40%
-0.32
-182.55%
0.38
+45.45%
0.26
Beginning Cash Position
14.18
-33.96%
21.46
-34.53%
32.79
-47.60%
62.56
End Cash Position
257.62
+1717.45%
14.18
-33.96%
21.46
-34.53%
32.79
Free Cash Flow
-6.73
+63.88%
-18.62
+49.55%
-36.91
+14.42%
-43.13
Income Tax Paid Supplemental Data
0.01
0.00
0.00
0.00
Amortization Of Securities
0.00
-100.00%
0.07
+116.24%
-0.43
-176.15%
0.57
Common Stock Issuance
—
0.00
-100.00%
2.88
+467.26%
0.51
Issuance Of Capital Stock
266.81
0.00
-100.00%
2.88
+467.26%
0.51
Net Preferred Stock Issuance
266.81
0.00
—
—
Preferred Stock Issuance
266.81
0.00
—
—
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category